Data Collection
Baseline values were collected on all patients. During ECMO therapy, the lowest thrombocyte count, lowest hematocrit, and highest antifactor Xa activity and ACT value were recorded, as was survival 6 months after ECMO initiation. Patient charts were reviewed for clinical evidence of neurologic dysfunction during ECMO treatment, defined as seizures, loss of consciousness, and loss of brainstem reflexes or new-onset anisocoria. All cerebral imaging studies were reviewed by S.K. and U.S.
In accordance with Swiss law, autopsies were only performed when the next of kin rendered approval. Available autopsy records and slides were reviewed by E.J.R. If the macroscopic autopsy examination showed only evidence of diffuse hypoxic-ischemic changes, a follow-up histologic examination was not routinely performed. The cerebral imaging or autopsy findings were classified as either probably related to or unlikely due to ECMO therapy by U.S. and E.J.R., who were blinded to each other's assessment. Because no known pathognomonic morphologic or imaging findings for ECMO-associated neurologic injury exist, the classification was based on the features of the acute illness, localization, and the neuropathologic findings. More
This retrospective single-center study investigated the incidence of neurologic injury as determined by autopsy or cerebral imaging in 74 patients undergoing extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome. Seventy-three percent of patients were treated with venovenous and 27% with venoarterial ECMO. ECMO-associated intracerebral hemorrhage was diagnosed in 10.8% of patients. There were no cases of ischemic stroke. Clinical characteristics did not differ between patients with and without neurologic injury. Sixmonth survival was 13% (Wilson confidence interval, 2%-47%) in patients with severe intracerebral hemorrhage compared to an overall survival rate of 57% (Wilson confidence interval, 45%-67% specifically, the presence of hemorrhagic and/or ischemic lesions not attributable to the underlying disease was considered related to ECMO therapy.
Statistical Analysis
The primary outcome of the study was the incidence of neurologic injury on ECMO, while survival, baseline values, intensive care unit, and ECMO characteristics were secondary outcome parameters. Continuous variables of baseline-, intensive care unit-, and ECMO-specific parameters were compared between patients with and without neurologic injury using the Mann-Whitney U test. Categorical variables were compared using Pearson χ 2 test or Fisher exact test, as appropriate. All P values were 2 sided and considered statistically significant if P ≤ .05.
Due to the retrospective nature of the study, the number of patients available was given. Assuming an overall survival of 62%, a survival of injured patients of 20%, and a proportion of injured patients of 11%, the survival of noninjured patients would be 67%. Based on 74 patients, and a significance level of 5%, the Fisher exact test was calculated to have a power of 65%.
Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM Corp, Armonk, NY).
RESULTS
During the study period of 6 years, a total of 309 ECMO runs were performed at our institution. Of these, 74 patients suffering from severe ARDS received ECMO therapy. Fortytwo patients (57%) survived to 6 months after ECMO initiation (Wilson confidence interval, 45%-67%).
Cerebral imaging was performed in 20 patients. Due to unsatisfactory quality, 1 imaging study was not eligible for investigational purposes. Nineteen patients underwent computed tomography evaluation, and 1 patient underwent magnetic resonance tomography. An autopsy was performed in 18 patients. In 1 patient, the autopsy did not include the brain.
Cerebral imaging and/or autopsy was thus performed in 23 of 32 nonsurvivors (72%), while cerebral imaging was performed in 8 of 42 survivors (19%).
Evidence of presumed ECMO-associated neurologic injury was diagnosed by cerebral imaging and/or autopsy in 8 patients (10.8%). In all cases, ICH with variable localization and dimensions were diagnosed ( Table and Figure) . There were no cases of ischemic stroke.
In 3 patients, neurologic injury was assessed as not being associated with ECMO therapy. Two patients with sepsis had large intraparenchymal hemorrhagic lesions, which were considered likely due to septic-embolic origin. A single patient diagnosed with posterior reversible leukoencephalopathy syndrome in the clinical setting of preeclampsia had multiple, bihemispheric ischemic cerebral infarcts with hemorrhagic transformation.
Patients In patients with neurologic injury, 1 patient (13%) received v-a cannulation compared to 19 patients (29%) without neurologic injury. The rate of neurologic injury did not differ between v-a and v-v cannulation mode (P = .4, Fisher exact test).
Seven of 8 patients with ECMO-associated neurologic injury died, yielding a survival rate of 13%. Therapy was withdrawn in 5 patients due to severe neurologic injury and complete dependence on ECMO support. Two patients died due to complications: hemorrhagic shock after accidental dislocation of the ECMO cannula and circulatory failure due to pericardial tamponade.
The diagnosis of ECMO-associated neurologic injury was made at a median of 6 days (IQR, 4-23 days) after ECMO initiation. Patients with ECMO-associated neurologic injury died at a median of 14 days (IQR, 6-31 days) after ECMO initiation.
DISCUSSION
In our cohort of 74 patients requiring ECMO for ARDS, ECMO-associated intracranial hemorrhage was diagnosed in 10.8% of patients with a 6-month survival of 13% (Wilson confidence interval, 2%-47%) compared to 57% overall (Wilson confidence interval, 45%-67%). Although direct comparison of our results with those found in other studies is difficult due to diverse study populations, methods, and the definition of neurologic injury, our data are consistent with previously reported incidences ranging from 3% to 19%. 2, 4, 5, [7] [8] [9] We were unable to identify a precise trigger for this devastating event in our cohort. Logistical challenges that precluded neuroimaging studies in all ECMO patients may have resulted in an underestimation of the true incidence of neurologic injury in our study. In contrast to the 2% reported by Luyt et al, 5 ischemic stroke was not diagnosed in our study population.
The impact of ICH on patient outcome in our report is also consistent with published mortality rates of 60%-92%. 2, 7, 9 The principal finding in our study on cerebral imaging and autopsy was major ICH with fatal outcome, while small ICH was diagnosed only in a minority of patients. This observation emphasizes the high probability for underdiagnosis of neurologic injury in minor events. Hematomas diagnosed at autopsy were smaller than the large spaceoccupying, intraparenchymal hematomas seen in patients where therapy was withdrawn. Additional condition which potentially leads to an intracerebral hemorrhage or ischemia by itself.
Regardless of the extent of hemorrhage, the treatment of ICH under ECMO support is especially challenging. Ongoing anticoagulation may worsen hemorrhage, while discontinuation may trigger thrombotic events. The surgical treatment of ICH remains controversial without proven benefit for patients under mechanical support in a 2014 case series. 10 However, the study largely involved patients with left ventricular assist devices (92%) and not ECMO (8%). 
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Changes in coagulation and excessive anticoagulation are potential risk factors for ICH in ARDS patients treated on ECMO. To date, no widely accepted protocol exists for determining the optimal degree of anticoagulation with existing approaches to anticoagulation differ widely between ECMO centers. 8 Although the precise onset of intracranial bleeding was unclear in our patients, we found no difference in anticoagulation or platelet counts between patients with or without neurologic injury. Our patient population had no evidence of vascular malformations or pathology as a potential risk factor for ICH. Bleeding was mainly localized to the supratentorial compartment, not clearly corresponding to a specific vascular territory or cannulation method. Data regarding this issue are sparse and inconsistent, with Risnes et al 3 reporting a higher frequency of late cerebral sequelae in v-a-cannulated patients. Intraparenchymal hemorrhage occurred spontaneously or as a secondary event in ischemic areas of the brain.
In conclusion, our report demonstrates that severe ICH is a devastating event linked to high mortality in patients undergoing ECMO for severe ARDS. To reduce the incidence of ICH in patients undergoing ECMO, more studies are needed to better define risk factors and the causes of ECMO-associated ICH, as well as to identify monitoring strategies to facilitate early diagnosis and optimal anticoagulation. E 
